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SUMMARY – Sunitinib is an orally administered multikinase inhibitor. Th is therapy can provoke 
uncommon side eff ects such as pancytopenia, tumor lysis syndrome, cardiac disorders, thromboem-
bolic incidents, intestinal perforation, pancreatitis, acute renal failure, etc. We report a case of a 
63-year-old female admitted to the hospital due to abdominal pain, nausea, vomiting and elevated 
blood pressure. One month earlier, sunitinib therapy for metastatic renal cell carcinoma was initiated. 
During the fi rst cycle of therapy, after three weeks of sunitinib 50 mg daily, symptoms started and she 
stopped taking the drug. At admission, laboratory tests revealed elevated serum and urine amylase, 
C-reactive protein, urea and creatinine, and lowered platelet and leukocyte counts and hemoglobin 
value. Urine test showed proteinuria, erythrocyturia, leukocyturia and granulated cylinder. Th e patient 
was diagnosed with acute pancreatitis grade III, acute renal failure grade II, pancytopenia and urinary 
infection, and was hospitalized for fi ve days. She was treated symptomatically and with antibiotic 
therapy because of persistently elevated C-reactive protein and pathologic urinary sediment, which led 
to subjective and clinical improvement. Acute pancreatitis, renal insuffi  ciency and pancytopenia are 
rarely described side eff ects of sunitinib therapy, and clear connection between these conditions and 
drug activity is not yet determined. Medical specialists who prescribe and treat patients with sunitinib 
should be aware of the possible occurrence of these conditions and perform regular checkups of suni-
tinib treated patients.
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Introduction
Sunitinib is an orally administered multikinase in-
hibitor that targets several tyrosine kinase inhibitors 
implicated in tumor growth, pathologic angiogenesis, 
and metastatic progression1,2. According to registra-
tion studies, common side eff ects reported in at least 
20% of patients include hypertension, fatigue, gastro-
intestinal disorders (decreased appetite, diarrhea, sto-
matitis, nausea, dyspepsia, esophagitis), skin disorders, 
hematologic disorders (anemia, thrombocytopenia, 
granulocytopenia), hypothyroidism, etc. Uncommon 
side eff ects (>1:1000-<1:100 cases) include pancyto-
penia, tumor lysis syndrome, cardiac disorders, throm-
boembolic incidents, intestinal perforation, pancreati-
tis, Stevens-Johnson syndrome, acute renal failure and 
proteinuria3-5. We report a case of few uncommon 
sunitinib therapy side eff ects in a patient with meta-
static renal cell carcinoma (mRCC).
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A 63-year-old woman with medical history of well 
regulated hypertension, adult renal polycystosis and 
chronic renal failure stage 3A (glomerular fi ltration 
rate (GFR) 47.7 mL/min) was admitted to the hospi-
tal due to abdominal pain and nausea, vomiting and 
elevated blood pressure (up to 180/130 mm Hg), 
which had started gradually one week before. Th e pa-
tient noticed that symptoms started three weeks after 
sunitinib therapy for mRCC had been initiated. In 
June 2010, the patient underwent radical right sided 
nephrectomy due to renal adenocarcinoma. In March 
2012, lung metastases were verifi ed by positron emis-
sion tomography-computed tomography. In May 
2012, fi rst line treatment for mRCC with sunitinib 
was initiated. During the fi rst cycle of 50 mg sunitinib 
daily, the symptoms started after three weeks, so she 
stopped taking the drug. On hospital admission, labo-
ratory tests revealed elevated serum and urine amylase 
(138 and 1997 U/L), C-reactive protein (CRP, 90 
mg/L), urea (13.4 mmol/L) and creatinine (213 
μmol/L; GFR 28.2 mL/min), and lowered platelet 
(39x109/L) and leukocyte (2.56x109/L) counts and he-
moglobin value (100 g/L). Urine test showed protein-
uria, erythrocyturia, leukocyturia and granulated cylin-
der. Abdominal ultrasound revealed bilateral pleural 
eff usions, free fl uid in lower abdomen, enlarged left 
kidney with canal system dilatation and gallbladder 
concrement of 3 cm in size without bile duct dilatation 
but the pancreas was not visualized due to meteorism. 
Th e patient was diagnosed with acute pancreatitis 
grade III, acute renal failure grade II (worsening of 
chronic kidney failure), pancytopenia and urinary in-
fection (graduation according to Common Terminol-
ogy Criteria for Adverse Events v. 4.03). She was 
treated symptomatically and, because of persistently 
elevated CRP and pathologic urine sediment, with an-
tibiotic therapy (amoxicillin/clavulanic acid), which 
led to subjective and clinical improvement (decrease of 
serum and urine amylase and CRP, initial decrease of 
creatinine value). Antihypertensive therapy was also 
modifi ed. Th e patient was discharged after fi ve days 
and further checkups were provided by oncologist in 
outpatient care. After recovery, in October 2012, the 
patient started therapy with sorafenib, which she toler-
ated well.
Discussion
Acute pancreatitis, acute renal failure and pancyto-
penia, which were all found in our patient, are uncom-
mon side eff ects of sunitinib therapy. In a phase III 
study conducted in 2007, Motzer et al. compared the 
effi  cacy of sunitinib (375 patients) versus interferon 
alfa (360 patients) for mRCC; increase in amylase and 
lipase level was recorded in 84 (22.4%) patients in 
sunitinib arm (20.2% of which were grade III and 
4.8% grade IV); there were no cases of acute pancre-
atitis in that study3. To the best of our knowledge, only 
three cases of acute pancreatitis have been reported in 
the literature, i.e. one patient on combined tyrosine ki-
nase therapy treated for non-small-cell lung carcino-
ma, one patient on combined therapy with sunitinib, 
gemcitabine and cisplatin treated for high-grade uro-
thelial carcinoma, and one patient on combined radio-
immunotherapy for hepatocellular carcinoma; none 
has been reported in patients receiving sunitinib for 
mRCC6-8. Considering renal toxicity, according to the 
study by Motzer et al., increased creatinine values were 
recorded in 66 (17.6%, of which only one grade III 
case) patients receiving sunitinib for mRCC3. Th ere 
are few retrospective studies conducted in patients 
with renal impairment at the start of sunitinib therapy, 
suggesting that sunitinib is safe in that population 
(metabolized primarily in the liver) but often causes 
creatinine level increase and demands dose adjustment 
due to the higher incidence of non-renal toxicity and 
hypertension9-12. Th ere are few case reports on acute 
renal failure in patients receiving sunitinib13,14. Al-
though our patient had a history of chronic renal in-
suffi  ciency, during sunitinib therapy she experienced 
worsening of her usually stable disease (acute-on-
chronic renal failure) and we could not determine with 
certainty if worsening of her renal function was a con-
sequence of dehydration due to vomiting or an eff ect 
of sunitinib. According to registration studies, anemia, 
leukocytopenia and thrombocytopenia are common 
adverse events associated with sunitinib therapy; how-
ever, to the best of our knowledge, pancytopenia has 
not yet been reported in postmarketing experience3,15.
Conclusion
Acute pancreatitis, renal insuffi  ciency and pancyto-
penia are rarely described side eff ects of sunitinib ther-
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apy and clear connection between these conditions 
and drug activity has not yet been determined. Medi-
cal specialists who prescribe and treat patients with 
sunitinib should be aware of the possible occurrence of 
these conditions and perform regular checkups of 
treated patients.
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Sažetak
RIJETKE NUSPOJAVE TERAPIJE SUNITINIBOM 
U BOLESNICE S METASTATSKIM KARCINOMOM BUBREGA: PRIKAZ SLUČAJA
R. Šeparović, M. Pavlović, T. Silovski, H. Silovski i A. Tečić Vuger
Sunitinib je oralni multikinazni inhibitor. Liječenje može izazvati pojavu rijetkih nuspojava kao što su pancitopenija, 
sindrom lize tumora, srčani poremećaji, tromboembolijski incidenti, perforacija crijeva, pankreatitis, akutno zatajenje bubre-
ga itd. Ovdje prikazujemo slučaj 63-godišnje bolesnice hospitalizirane zbog bolova u trbuhu, mučnine, povraćanja i poviše-
nog krvnog tlaka. Mjesec dana ranije je započela liječenje sunitinibom zbog metastatskog karcinoma bubrega. U bolesnice su 
se tijekom prvog ciklusa liječenja, nakon tri tjedna uzimanja 50 mg sunitiniba na dan, pojavili navedeni simptomi zbog čega 
je bolesnica prekinula uzimati lijek. Pri prijmu u bolnicu su laboratorijski nalazi pokazali povišene vrijednosti serumskih i 
mokraćnih amilaza, C-reaktivnog proteina, ureje i kreatinina, sniženi broj trombocita i leukocita te sniženu vrijednost hemo-
globina. Postavljena je dijagnoza akutnog pankreatitisa gr. III., akutnog bubrežnog zatajenja gr. II, pancitopenije i urinarne 
infekcije te je bolesnica hospitalizirana tijekom pet dana. Liječena je simptomatski te antibiotikom zbog povišene vrijednosti 
C-reaktivnog proteina i patološkog sedimenta mokraće, što je dovelo do subjektivnog i kliničkog poboljšanja stanja. Akutni 
pankreatitis, bubrežno zatajenje i pancitopenija su rijetko opisivane nuspojave primjene sunitiniba i jasna veza između tih 
stanja i aktivnosti lijeka još nije utvrđena. Specijalisti koji propisuju i liječe bolesnike sunitinibom trebali bi biti svjesni 
 mogućnosti pojave ovih stanja i provoditi redovite kontrole u bolesnika liječenih ovim lijekom.
Ključne riječi: Sunitinib; Karcinom bubrežnih stanica; Uzimanje lijekova, nuspojave i štetna djelovanja; Pankreatitis; Akutna 
bubrežna trauma; Pancitopenija
